Skip to main content

Presentati i Late-Breaking Clinical Trials di ESC 2022

Redazione By 30 Giugno 2022No Comments
Dai congressiNews
Clinical trials ESC 2022

Sono stati resi noti i Late-Breaking Clinical Trials che verranno presentati nel corso delle Hot Line Sessions di ESC 2022, il prossimo Congresso dell’European Society of Cardiology in programma dal 26 al 29 agosto 2022 a Barcellona. Come sempre la redazione di Cardioinfo sarà presente al Congresso per interviste, news e approfondimenti.

“Abbiamo creato un programma Hot Lines davvero eccezionale per il Congresso ESC 2022 – ha commentato Stephen Windecker, chairman nel comitato scientifico dell’evento – e incoraggio tutti a esplorarli. I risultati di questi importanti studi clinici hanno il potenziale per migliorare gli outcome dei pazienti, avere un impatto sulla pratica clinica e informare le future linee guida”. Di seguito la lista degli studi, divisi per giornata congressuale:

Venerdì 26 agosto:
HOT LINE SESSION 1:
  • TIME – The Treatment in Morning versus Evening study.
  • A polypill strategy in secondary prevention: results of the SECURE trial
  • PERSPECTIVESacubitril/valsartan and cognitive function in HFmrEF and HFpEF
Sabato 27 agosto:
HOT LINE SESSION 2:
  • DANCAVAS – Screening and intervention to prevent cardiovascular disease.
  • ADVOR – Acetazolamide in acute heart failure.
  • DANFLU-1 – High-dose vs. standard-dose quadrivalent influenza vaccine in elderly adults.
  • BOX – Oxygen therapy in comatose OHCA patients.
  • BOX – Optimizin blood pressure in post-resuscitation care.
HOT LINE SESSION 3:
  • REVIVED – Percutaneous Revascularisation for Ischaemic Ventricular Dysfunction.
  • ALL-HEART – Allopurinol and cardiovascular outcomes in ischaemic heart disease.
  • EchoNet-RCT – Safety and Efficacy Study of AI LVEF.
HOT LINE SESSION 4:
  • DELIVER Dapagliflozin in Heart Failure with Mildly Reduced and Preserved Ejection Fraction.
  • Pooled analysis of DAPA-HF and DELIVER.
  • A Pre-Specified Meta-Analysis of DELIVER and EMPEROR-Preserved.
Domenica 28 agosto:
HOT LINE SESSION 5:
  • INVICTUS – Rivaroxaban versus VKA for rheumatic atrial fibrillation.
  • PACIFIC-AMI – Efficacy and safety of factor XIa inhibitor asundexian on top of dual antiplatelet therapy after acute myocardial infarction.
  • PACIFIC-STROKE – Phase 2 Program of AntiCoagulation via Inhibition of FXIa by the oral Compound BAY 2433334 – non-cardioembolic STROKE study.
  • AXIOMATIC-SSP: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.
HOT LINE SESSION 6:
  • eBRAVE-AF – Smartphone-based AF screening.
  • Causal AI substantially improves the validity of estimating cardiovascular risk and benefit.
  • AI-ENHANCED detection of Aortic Stenosis.
HOT LINE SESSION 7:
  • DanNICAD-2 – Perfusion scanning with MR or PET after a positive CT coronary angiography.
  • The PRE18FFIR trial: Coronary Plaque Activity to Predict Recurrent Events.
  • The FRAME-AMI trial.
Lunedì 29 agosto:
HOT LINE SESSION 8:
  • ISCHEMIA-CKD EXTEND – Clinical Outcomes at 5 years of Follow-up.
  • 15-month results of the MASTER DAPT trial.
  • FOURIER-OLE: Primary Results.
  • FIDELITY: Causes of mortality.
  • PARADISE-MI trial – Win Ratio Analysis.
HOT LINE SESSION 9:
  • CTT meta-analysis of the effects of statins on muscle symptoms.
  • MTT – Assessing the effects of ARBs and beta-blockers in Marfan Syndrome.
  • PANTHER – P2Y12 inhibitor versus aspirin monotherapy in patients with coronary artery disease.
  • RTC – Radial versus femoral access for coronary procedures.
HOT LINE SESSION 10:
  • COVID-PACT – Antithrombotic therapy in critically Ill COVID-19 patients.
  • ACT Outpatient trial.
  • ACT Inpatient trial.